BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 19224764)

  • 1. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
    Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
    Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
    Singh VY; Chacko G; Chacko AG; Rajshekhar V
    Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
    J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
    Kros JM; Gorlia T; Kouwenhoven MC; Zheng PP; Collins VP; Figarella-Branger D; Giangaspero F; Giannini C; Mokhtari K; Mørk SJ; Paetau A; Reifenberger G; van den Bent MJ
    J Neuropathol Exp Neurol; 2007 Jun; 66(6):545-51. PubMed ID: 17549014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
    Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
    Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
    J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
    Idbaih A; Dalmasso C; Kouwenhoven M; Jeuken J; Carpentier C; Gorlia T; Kros JM; French P; Teepen J; Broët P; Delattre O; Mokhtari K; Sanson M; Delattre JY; van den Bent M; Hoang-Xuan K
    J Neurooncol; 2011 Jun; 103(2):221-30. PubMed ID: 20820870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
    J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
    Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.
    Scheie D; Meling TR; Cvancarova M; Skullerud K; Mørk S; Lote K; Eide TJ; Helseth E; Beiske K
    Neuro Oncol; 2011 Nov; 13(11):1225-33. PubMed ID: 21856683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion.
    Pai T; Epari S; Desai S; Wadile A; Gupta T; Goda JS; Moiyadi A; Shetty P; Kane S; Jalali R
    Neurol India; 2017; 65(1):113-120. PubMed ID: 28084254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.
    Thiessen B; Maguire JA; McNeil K; Huntsman D; Martin MA; Horsman D
    J Neurooncol; 2003 Sep; 64(3):271-8. PubMed ID: 14558604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.